Modalis Therapeutics Corporation (TYO:4883)
Japan
· Delayed Price · Currency is JPY 56.00
-3.00 (-5.08%)
Mar 9, 2026, 3:30 PM JST
Modalis Therapeutics Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | - | - | - | 40 | 1 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | 3900.00% | -99.71% | Upgrade
|
| Gross Profit | - | - | - | 40 | 1 | Upgrade
|
| Selling, General & Admin | 231.81 | 220 | 248 | 213 | 196 | Upgrade
|
| Research & Development | 1,980 | 1,092 | 2,102 | 1,861 | 1,009 | Upgrade
|
| Other Operating Expenses | - | 25 | 20 | 29 | 35 | Upgrade
|
| Operating Expenses | 2,212 | 1,337 | 2,370 | 2,103 | 1,240 | Upgrade
|
| Operating Income | -2,212 | -1,337 | -2,370 | -2,063 | -1,239 | Upgrade
|
| Interest Expense | -2.8 | -8 | -15 | -4 | -1 | Upgrade
|
| Interest & Investment Income | 3.85 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 10.5 | 64 | 39 | 76 | 12 | Upgrade
|
| Other Non Operating Income (Expenses) | 60.18 | -23 | -6 | -4 | 1 | Upgrade
|
| EBT Excluding Unusual Items | -2,140 | -1,304 | -2,352 | -1,995 | -1,227 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -2 | Upgrade
|
| Asset Writedown | -11.09 | - | -38 | -996 | - | Upgrade
|
| Other Unusual Items | - | -13 | - | 285 | 485 | Upgrade
|
| Pretax Income | -2,151 | -1,317 | -2,390 | -2,706 | -744 | Upgrade
|
| Income Tax Expense | 1.54 | - | 1 | -4 | -6 | Upgrade
|
| Net Income | -2,153 | -1,317 | -2,391 | -2,702 | -738 | Upgrade
|
| Net Income to Common | -2,153 | -1,317 | -2,391 | -2,702 | -738 | Upgrade
|
| Shares Outstanding (Basic) | 77 | 46 | 31 | 29 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 77 | 46 | 31 | 29 | 29 | Upgrade
|
| Shares Change (YoY) | 67.52% | 48.96% | 6.39% | 1.23% | 9.12% | Upgrade
|
| EPS (Basic) | -27.86 | -28.55 | -77.21 | -92.83 | -25.67 | Upgrade
|
| EPS (Diluted) | -27.86 | -28.55 | -77.21 | -92.83 | -25.67 | Upgrade
|
| Free Cash Flow | -2,121 | -1,432 | -2,293 | -2,092 | -854 | Upgrade
|
| Free Cash Flow Per Share | -27.45 | -31.05 | -74.05 | -71.87 | -29.70 | Upgrade
|
| Gross Margin | - | - | - | 100.00% | 100.00% | Upgrade
|
| Operating Margin | - | - | - | -5157.50% | -123900.00% | Upgrade
|
| Profit Margin | - | - | - | -6755.00% | -73800.00% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -5230.00% | -85400.00% | Upgrade
|
| EBITDA | - | -1,336 | -2,369 | -1,940 | -1,162 | Upgrade
|
| D&A For EBITDA | - | 0.73 | 0.73 | 123 | 77 | Upgrade
|
| EBIT | -2,212 | -1,337 | -2,370 | -2,063 | -1,239 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.